NasdaqCM - Nasdaq Real Time Price ? USD Aditxt, Inc. (ADTX) Follow Compare 1.0600 -0.0500 (-4.50%) As of 2:25 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy The latest update is out from Aditxt, Inc. ( (ADTX) ). Amro Albanna, CEO of Aditxt, Inc., recently held an informative stakeholder update and Q&A session to provide transparency and clarity about the company’s direction and strategies. The session addressed key concerns such as NASDAQ compliance misconceptions, capital needs for a microcap company like Aditxt, and the rationale behind recent equity line actions. Albanna emphasized the importance of having access to efficient capital to sustain a TipRanks ? 4 days ago ADTX -4.50% Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval MOUNTAIN VIEW, Calif., October 10, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) ("Appili") has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will be held virtually on Nov Business Wire ? 7 days ago ADTX -4.50% APLIF Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time MOUNTAIN VIEW, Calif., October 09, 2024--Aditxt, Inc. ("Aditxt" "Company") (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company’s latest developments and will address pre-submitted questions. Business Wire ? 8 days ago ADTX -4.50% Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem MOUNTAIN VIEW, Calif. & SAN DIEGO, October 08, 2024--Aditxt, Inc. ("Aditxt" ) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), a pioneer in women's health, today announced the completion of the Third Parent Equity Investment under the Amended and Restated Merger Agreement, as amended (the "Agreement"). This investment further strengthens the strategic and collaborative relationship between the tw Business Wire ? 9 days ago EVFM ADTX -4.50% Aditxt Delivers Shareholder Update and 2024 Year-End Plan MOUNTAIN VIEW, Calif., October 03, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end. Business Wire ? 14 days ago APLIF EVFM ADTX -4.50% Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 MOUNTAIN VIEW, Calif., September 27, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on October 2, 2024, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockhold Business Wire ? 20 days ago ADTX -4.50% Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt MOUNTAIN VIEW, Calif., September 24, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), today filed a preliminary proxy to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the "Merger Agreement"), with Aditxt and Adifem, Inc., a who Business Wire ? 23 days ago ADTX -4.50% EVFM Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 MOUNTAIN VIEW, Calif. & SAN DIEGO, September 20, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. ("Pearsanta"), has entered into a Market Development Collaboration Agreement (the "Agreement") with women’s health pioneer Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM) focused on Pearsanta’s blood-based diagnostic test for endometriosis Business Wire ? 27 days ago ADTX -4.50% EVFM Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 MOUNTAIN VIEW, Calif. & SAN DIEGO, September 09, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem") today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the "Second Amendment"), under which Aditxt intends to acquire Evofem. Business Wire ? last month EVFM ADTX -4.50% Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic? Prostate Test, Targeting Early Detection in High-Risk Patients MOUNTAIN VIEW, Calif., September 04, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has submitted a grant application to the Prostate Cancer Research Program (PCRP) under the Department of Defense (DoD) Implementation Science Award funding mechanism seeking $2 million in funding. This non-dilutive funding initiative aims to advance the early det Business Wire ? last month ADTX -4.50% Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024. Business Wire ? last month EVFM ADTX -4.50% APLIF Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic? Endometriosis Test (MET?) and Mitomic? Prostate Test (MPT?) MOUNTAIN VIEW, Calif., August 26, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Business Wire ? last month ADTX -4.50% Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics MOUNTAIN VIEW, Calif., August 21, 2024--Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF) ("Appili"), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential b Business Wire ? last month APLIF ADTX -4.50% Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: PR Newswire ? 2 months ago EVFM ADTX -4.50% Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans MOUNTAIN VIEW, Calif., August 13, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising innovations, announced the successful passage of all proposals at its recent annual shareholders' meeting. Business Wire ? 2 months ago ADTX -4.50% Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MOUNTAIN VIEW, Calif., August 09, 2024--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of a previously announced registered direct offering price at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,130,189 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.06 pe Business Wire ? 2 months ago ADTX -4.50% Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MOUNTAIN VIEW, Calif., August 09, 2024--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 1,130,189 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.06 per share (o Business Wire ? 2 months ago ADTX -4.50% Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer MOUNTAIN VIEW, Calif., August 07, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. ("Pearsanta") has submitted a proposal for the Clinical Trial Translational Endpoints Research Award to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense. The proposal aims to validate a novel assay based on Pearsanta’s proprietary Mitomic Business Wire ? 2 months ago ADTX -4.50% Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ETSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webca GlobeNewswire ? 2 months ago ADTX -4.50% EVFM Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition MOUNTAIN VIEW, Calif., July 25, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and its wholly-owned subsidiary, Adivir, Inc., have entered into a second Amending Agreement (the "Amending Agreement") with Appili Therapeutics Inc. ("Appili") (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures. Under the Amending Agree Business Wire ? 2 months ago ADTX -4.50% APLIF Performance Overview Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ADTX S&P 500 YTD -99.60% +22.55% 1-Year -99.73% +33.65% 3-Year -100.00% +30.73%
